Sanofi springs for Protein Sciences | July 17, 2017 Issue - Vol. 95 Issue 29 | Chemical & Engineering News
Volume 95 Issue 29 | p. 17 | Concentrates
Issue Date: July 17, 2017

Sanofi springs for Protein Sciences

Department: Business
Keywords: Vaccines, acquisition, vaccine, influenza

Sanofi has agreed to buy Protein Sciences, a vaccines manufacturer, for $650 million. Based in Connecticut, Protein Sciences received FDA approval in October for Flublok Quadrivalent, which it touts as the only recombinant protein-based influenza vaccine to be cleared by the agency. “The acquisition of Protein Sciences will allow us to broaden our flu portfolio with the addition of a non-egg-based vaccine,” says David Loew, head of Sanofi’s vaccines division. Sanofi will pay as much as $100 million more if certain milestones are hit.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment